Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

ConclusionsBoth a two-dose of inactivated SARS-CoV-2 vaccine at 0 –21 days and 0–28 days regimens significantly improved SARS-CoV-2 neutralizing antibody level compared to the 0–14 days regimen in high-risk occupational population, with seroconversion rates of 100.0%.Trial registrationChinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706. Registered 1 January 2021,www.chictr.org.cn.Graphical Abstract
Source: Infectious Diseases of Poverty - Category: Infectious Diseases Source Type: research